Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722512 · ClinicalTrials.gov registry record · Phase 1
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
A Phase 1 study, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02722512 is a Phase 1 study that was terminated before completion, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 10 participants.
The verdict
NCT02722512, a Phase 1 study, was terminated before completion, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine is an feasible and safe treatment for pediatric patients with newly-diagnosed High-Grade Gliomas or recurrent, resectable High-Grade Gliomas and Ependymomas.
Interventions
- RADIATION Radiation
- PROCEDURE Tumor Resection
- BIOLOGICAL Heat Shock Protein Peptide Complex-96 (HSPPC-96)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02722512
The ClinicalTrials.gov registry entry for NCT02722512 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation is the first listed.
NCT02722512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02722512 about?
NCT02722512 is a clinical study titled "Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine". The purpose of this study is to determine whether Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine is an feasible and safe treatment for pediatric patients with newly-diagnosed High-Grade Gliomas or recurrent, resectable High-Grade Gliomas and Ependymomas.
What is the current status of trial NCT02722512?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-07. Estimated completion is 2019-11-13.
What interventions are being tested in trial NCT02722512?
The interventions under investigation include: Radiation (RADIATION), Tumor Resection (PROCEDURE), Heat Shock Protein Peptide Complex-96 (HSPPC-96) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02722512?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.